IRIS Accounts Production v25.1.3.33 08791538 director 1.12.23 30.11.24 30.11.24 false true false false true false iso4217:GBPiso4217:USDiso4217:EURxbrli:sharesxbrli:pureutr:tonnesutr:kWh087915382023-11-30087915382024-11-30087915382023-12-012024-11-30087915382022-11-30087915382022-12-012023-11-30087915382023-11-3008791538ns15:EnglandWales2023-12-012024-11-3008791538ns14:PoundSterling2023-12-012024-11-3008791538ns10:Director12023-12-012024-11-3008791538ns10:PrivateLimitedCompanyLtd2023-12-012024-11-3008791538ns10:SmallEntities2023-12-012024-11-3008791538ns10:AuditExemptWithAccountantsReport2023-12-012024-11-3008791538ns10:SmallCompaniesRegimeForDirectorsReport2023-12-012024-11-3008791538ns10:SmallCompaniesRegimeForAccounts2023-12-012024-11-3008791538ns10:FullAccounts2023-12-012024-11-3008791538ns10:RegisteredOffice2023-12-012024-11-3008791538ns5:CurrentFinancialInstruments2024-11-3008791538ns5:CurrentFinancialInstruments2023-11-3008791538ns5:ShareCapital2024-11-3008791538ns5:ShareCapital2023-11-3008791538ns5:RetainedEarningsAccumulatedLosses2024-11-3008791538ns5:RetainedEarningsAccumulatedLosses2023-11-3008791538ns5:PlantMachinery2023-12-012024-11-3008791538ns5:LandBuildings2023-11-3008791538ns5:PlantMachinery2023-11-3008791538ns5:LandBuildings2023-12-012024-11-3008791538ns5:LandBuildings2024-11-3008791538ns5:PlantMachinery2024-11-3008791538ns5:LandBuildings2023-11-3008791538ns5:PlantMachinery2023-11-3008791538ns5:WithinOneYearns5:CurrentFinancialInstruments2024-11-3008791538ns5:WithinOneYearns5:CurrentFinancialInstruments2023-11-30
REGISTERED NUMBER: 08791538 (England and Wales)















UNAUDITED FINANCIAL STATEMENTS FOR THE YEAR ENDED 30 NOVEMBER 2024

FOR

CLEE PHARMA LIMITED

CLEE PHARMA LIMITED (REGISTERED NUMBER: 08791538)






CONTENTS OF THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 30 NOVEMBER 2024




Page

Company Information 1

Balance Sheet 2

Notes to the Financial Statements 3

Report of the Accountants 5

CLEE PHARMA LIMITED

COMPANY INFORMATION
FOR THE YEAR ENDED 30 NOVEMBER 2024







DIRECTOR: Ms K A Hogg





REGISTERED OFFICE: 23 Bilston Street
Sedgley
Dudley
West Midlands
DY3 1JA





REGISTERED NUMBER: 08791538 (England and Wales)





ACCOUNTANTS: Bytheway & Co Accountants Ltd
23 Bilston Street
Sedgley
Dudley
West Midlands
DY3 1JA

CLEE PHARMA LIMITED (REGISTERED NUMBER: 08791538)

BALANCE SHEET
30 NOVEMBER 2024

30/11/24 30/11/23
Notes £    £    £   
FIXED ASSETS
Tangible assets 4 366,848 36,909

CURRENT ASSETS
Debtors 5 47,126 23,853
Cash at bank and in hand 18,103 112,431
65,229 136,284
CREDITORS
Amounts falling due within one year 6 398,946 152,290
NET CURRENT LIABILITIES (333,717 ) (16,006 )
TOTAL ASSETS LESS CURRENT
LIABILITIES

33,131

20,903

CAPITAL AND RESERVES
Called up share capital 1 1
Retained earnings 33,130 20,902
SHAREHOLDERS' FUNDS 33,131 20,903

The company is entitled to exemption from audit under Section 477 of the Companies Act 2006 for the year ended 30 November 2024.

The members have not required the company to obtain an audit of its financial statements for the year ended 30 November 2024 in accordance with Section 476 of the Companies Act 2006.

The director acknowledges her responsibilities for:
(a)ensuring that the company keeps accounting records which comply with Sections 386 and 387 of the Companies Act 2006 and
(b)preparing financial statements which give a true and fair view of the state of affairs of the company as at the end of each financial year and of its profit or loss for each financial year in accordance with the requirements of Sections 394 and 395 and which otherwise comply with the requirements of the Companies Act 2006 relating to financial statements, so far as applicable to the company.

The financial statements have been prepared and delivered in accordance with the provisions applicable to companies subject to the small companies regime.

In accordance with Section 444 of the Companies Act 2006, the Income Statement has not been delivered.

The financial statements were approved by the director and authorised for issue on 3 June 2025 and were signed by:





Ms K A Hogg - Director


CLEE PHARMA LIMITED (REGISTERED NUMBER: 08791538)

NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 30 NOVEMBER 2024

1. STATUTORY INFORMATION

Clee Pharma Limited is a private company, limited by shares , registered in England and Wales. The company's registered number and registered office address can be found on the Company Information page.

2. ACCOUNTING POLICIES

Basis of preparing the financial statements
These financial statements have been prepared in accordance with Financial Reporting Standard 102 "The Financial Reporting Standard applicable in the UK and Republic of Ireland" including the provisions of Section 1A "Small Entities" and the Companies Act 2006. The financial statements have been prepared under the historical cost convention.

The company's financial statements are individual entity financial statements.

The company's financial statements are presented in Sterling and all values are rounded to the nearest pound.

Turnover
Turnover is measured at the fair value of the consideration received or receivable, excluding discounts, rebates, value added tax and other sales taxes.

Tangible fixed assets
Depreciation is provided at the following annual rates in order to write off each asset over its estimated useful life.
Plant and machinery etc - 33% on cost, 25% on reducing balance and 15% on reducing balance

Taxation
Taxation for the year comprises current and deferred tax. Tax is recognised in the Income Statement, except to the extent that it relates to items recognised in other comprehensive income or directly in equity.

Current or deferred taxation assets and liabilities are not discounted.

Current tax is recognised at the amount of tax payable using the tax rates and laws that have been enacted or substantively enacted by the balance sheet date.

Deferred tax
Deferred tax is recognised in respect of all timing differences that have originated but not reversed at the balance sheet date.

Timing differences arise from the inclusion of income and expenses in tax assessments in periods different from those in which they are recognised in financial statements. Deferred tax is measured using tax rates and laws that have been enacted or substantively enacted by the year end and that are expected to apply to the reversal of the timing difference.

Unrelieved tax losses and other deferred tax assets are recognised only to the extent that it is probable that they will be recovered against the reversal of deferred tax liabilities or other future taxable profits.

Hire purchase and leasing commitments
Rentals paid under operating leases are charged to profit or loss on a straight line basis over the period of the lease.

Pension costs and other post-retirement benefits
The company operates a defined contribution pension scheme. Contributions payable to the company's pension scheme are charged to profit or loss in the period to which they relate.

3. EMPLOYEES AND DIRECTORS

The average number of employees during the year was 1 (2023 - 1 ) .

CLEE PHARMA LIMITED (REGISTERED NUMBER: 08791538)

NOTES TO THE FINANCIAL STATEMENTS - continued
FOR THE YEAR ENDED 30 NOVEMBER 2024

4. TANGIBLE FIXED ASSETS
Plant and
Land and machinery
buildings etc Totals
£    £    £   
COST
At 1 December 2023 - 65,125 65,125
Additions 336,597 2,203 338,800
At 30 November 2024 336,597 67,328 403,925
DEPRECIATION
At 1 December 2023 - 28,216 28,216
Charge for year - 8,861 8,861
At 30 November 2024 - 37,077 37,077
NET BOOK VALUE
At 30 November 2024 336,597 30,251 366,848
At 30 November 2023 - 36,909 36,909

5. DEBTORS: AMOUNTS FALLING DUE WITHIN ONE YEAR
30/11/24 30/11/23
£    £   
Trade debtors 43,430 20,990
Other debtors 3,696 2,863
47,126 23,853

6. CREDITORS: AMOUNTS FALLING DUE WITHIN ONE YEAR
30/11/24 30/11/23
£    £   
Trade creditors 3,337 3,194
Amounts owed to group undertakings 296,494 32,010
Taxation and social security 99,115 117,086
398,946 152,290

CLEE PHARMA LIMITED

REPORT OF THE ACCOUNTANTS TO THE DIRECTOR OF
CLEE PHARMA LIMITED

The following reproduces the text of the report prepared for the director in respect of the company's annual unaudited financial statements. In accordance with the Companies Act 2006, the company is only required to file a Balance Sheet. Readers are cautioned that the Income Statement and certain other primary statements and the Report of the Director are not required to be filed with the Registrar of Companies.

As described on the Balance Sheet you are responsible for the preparation of the financial statements for the year ended 30 November 2024 set out on pages one to seven and you consider that the company is exempt from an audit.

In accordance with your instructions, we have compiled these unaudited financial statements in order to assist you to fulfil your statutory responsibilities, from the accounting records and information and explanations supplied to us.






Bytheway & Co Accountants Ltd
23 Bilston Street
Sedgley
Dudley
West Midlands
DY3 1JA


3 June 2025